128 filings
Page 4 of 7
6-K/A
cbnhp2 4j9ywr89ibqf
19 Jan 21
Current report (foreign) (amended)
6:25am
6-K
jmqlkq36q
13 Jan 21
Current report (foreign)
4:00pm
6-K
wqhl4uk0bd a6baj14c4
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
6-K/A
ho8dms2rpp2d91oc79c
4 Jan 21
Current report (foreign) (amended)
6:36am
6-K
ve5xzpi4tlsx3bt
4 Jan 21
ObsEva appoints David Renas as Chief Financial Officer
6:36am
6-K
awaga
10 Dec 20
Current report (foreign)
6:03am
6-K
oafuo
24 Nov 20
Current report (foreign)
6:03am
6-K
y48we
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
jo8e6fnssz
9 Nov 20
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
7:32am
6-K
i51uwzadkmy2bk
5 Nov 20
Index to Unaudited Condensed Consolidated Financial Statements
6:02am
6-K
vq99 glz4c0x0pu9vn
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
ik3uov rvhhnnqwl3
14 Aug 20
Current report (foreign)
4:24pm
6-K
rho2zx6sa6porgo965
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
k8caerad16q624f5trg
7 Jul 20
Current report (foreign)
3:39pm
6-K
awkq4vma2agorjemzs
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
7ob85lqg3wwdbk
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
zsrq5ew55u76gm g1h18
9 Jun 20
Current report (foreign)
4:10pm
6-K
duhja
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
6-K
vhwe9ez59w
8 May 20
ObsEva Annual General Meeting 2020
4:38pm
6-K
hjl0 upbz7x
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am